Hm Payson & CO Galectin Therapeutics Inc Transaction History
Hm Payson & CO
- $5.6 Billion
- Q1 2025
Shares
2 transactions
Others Institutions Holding GALT
# of Institutions
95Shares Held
11.2MCall Options Held
134KPut Options Held
353K-
Vanguard Group Inc Valley Forge, PA2.18MShares$10 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$7.16 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.27MShares$5.8 Million0.01% of portfolio
-
Jane Street Group, LLC New York, NY749KShares$3.43 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$3.05 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $272M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...